Phagenesis, a UK-based medical device company focused on the treatment of dysphagia, has expanded its series B round to $17m. It originally announced a €7m ($9.1m) first close led by Inventages, a life sciences firm backed by Switzerland-based food and nutrition corporation Nestlé, in autumn 2011. Founded in 2007 after it spun off from research…
Phagenesis expands series B round
Jun 5, 2013 •
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Resistance is futile: seven superconductor companies that want to change the world
From healthcare to fusion to quantum computing to space, superconductors have the potential to revolutionise the world. And the technology is finally ready to commercialise.
UK universities urged to lower spinout stakes
A new report recommends stakes of less than 25% but fails to address the issue of access to early-stage capital.
Feb 7, 2024
Mar 14, 2024
Monterey, CA (USA)
Jun 26, 2024